Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
CRM
IHD
RydaptⓇ - Multi-targeted kinase inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03591510 (CPKC412A2218)
Acute myeloid leukemia, pediatrics
Phase 2
20
Occurrence of dose limiting toxicities
Safety and Tolerability
Chemotherapy followed by Midostaurin
Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia
(AML)
Target Patients
Read-out Milesstone(s)
2026
Publication
TBD
124 Investor Relations | Q3 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation